Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib, Lanraplenib, and Tirabrutinib in Active Sjogren's Syndrome
NCT03100942Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of filgotinib, lanraplenib and tirabrutinib in Sjogren's syndrome (4 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants Fulfilling Protocol-Specified Response Criteria at 12 weeks. Started May 2017; status: completed.
02
Drugs
filgotiniblanraplenibtirabrutinib
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT03100942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100942.